.svg){kind=small}
The EU’s Joint Clinical Assessment (JCA) came into effect in January 2025, bringing a structured approach to evaluating new oncology drugs and ATMPs across Europe. While this harmonized process aims to enhance transparency and collaboration, the industry faces pressing challenges—from concerns about duplicated efforts to tight timelines for dossier preparation and PICO framework anticipation. Equally critical is the evolving role of patients in shaping HTA and reimbursement decisions, a topic gaining momentum under the JCA framework. This session featured two experts guiding us through these complexities. Justin Stindt of Justin Stindt Consultants will unpack the Challenges & Opportunities of JCA, sharing strategies to navigate this new landscape.
Dr. Andreas Reimann from admedicum then explored Patient Engagement as the New Prerequisite for Market Access, highlighting how timely involvement and patient preference data can drive successful outcomes. This session provided actionable insights into optimizing JCA processes and elevating the patient voice. Stay tuned for a dedicated Q&A after the presentations.
If you would like a copy of the slides presented, please contact us: info@admedicum.com
